Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 + Apatinib in Advanced HCC
NCT07749859Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in hepatocellular carcinoma (HCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07749859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749859.